Alivus Life Sciences Ltd

NSE: ALIVUS · BSE: 543322 · Pharmaceuticals & Biotechnology · 23 announcements

Share price: ₹1,380.00
Market cap: ₹16,942 Cr
Revenue (annual): ₹2,552 Cr
Net profit (annual): ₹564.5 Cr
P/E (TTM): 28.1×Sector 47.4×
Promoter holding: 74.87%+0.00% QoQ
FII holding: 5.54%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Earnings Call 5 Financial Results 4 Results Update 2 Merger & Restructuring 2 Employee Stock Options 2 Board Meeting Date 2 Annual General Meeting 2 Other Announcement 1 Debt & Borrowing 1 Business Update 1 Annual Report 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

4 announcements with these filters

30 Jul 2026 18:44 IST NSE

Financial Results

Alivus Life Sciences Q1 FY27 Results: Net Profit ₹160.1 Cr, Up 31.8% YoY

Alivus Life Sciences Ltd reported revenue from operations of ₹640.4 Cr (+6.4% YoY) and net profit of ₹160.1 Cr (+31.8% YoY) for Q1 FY27.

Key figure: Net profit ₹160.1 Cr · +31.8% YoY

Open full results → Read the filing ↗

14 May 2026 19:34 IST NSE

Financial Results

Alivus Life Sciences Q4 FY26 Results: Net Profit ₹162.7 Cr, Up 14.7% YoY

Alivus Life Sciences Ltd reported revenue from operations of ₹689.1 Cr (+6.1% YoY) and net profit of ₹162.7 Cr (+14.7% YoY) for Q4 FY26.

Key figure: Net profit ₹162.7 Cr · +14.7% YoY

Open full results → Read the filing ↗

14 May 2026 19:34 IST NSE

Financial Results

Alivus Life Sciences Financial Results

Alivus Life Sciences approved FY2025-26 audited results and recommended a ₹5 per share final dividend. The company reported annual revenue from operations of ₹2,551.83 Crore.

Read the filing ↗

13 Apr 2026 13:22 IST BSE

Financial Results

Alivus Life Sciences Q3 FY26 Results: Net Profit ₹150 Cr, Up 9.5% YoY

Alivus Life Sciences Ltd reported net profit of ₹150 Cr (+9.5% YoY) for Q3 FY26.

Key figure: Net profit ₹150 Cr · +9.5% YoY

Open full results → Read the filing ↗